Combined dapagliflozin and pioglitazone therapy in diabetic nephropathy: no added benefit beyond monotherapy in inflammation and fibrosis.

Naunyn Schmiedebergs Arch Pharmacol · 2026 · PMC12901098 · PMID 41006906

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

A similar trend was observed in the group receiving combination therapy; however, it did not reach statistical significance (Fig. 6 G).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.